MIAMI, FL / ACCESS Newswire / April 24, 2025 / For decades, the men's health space has remained largely stagnant-held back by legacy brands offering generic solutions and treatment protocols that too often felt like quick fixes rather than genuine care. The result has been an industry shaped by stigma, limited access, and minimal innovation.

That landscape is beginning to change. Mangoceuticals Inc. (Nasdaq:MGRX) is taking a different approach, developing products that merge clinical rigor with user-centric design-responding to how people actually live today. With offerings that now span men's ED, hormonal balance, hair restoration, and weight loss-alongside a recently launched women's wellness platform, PeachesRx-the company is reshaping expectations across multiple health categories.

Treatment Reimagined for Today's World

Among the company's most notable developments is Mango, a flagship product that addresses erectile dysfunction (ED) in a way that feels more modern, discreet, and accessible. While ED remains a common issue-impacting over 70% of men at some point-treatment solutions have long felt dated, often defined by clinical detachment and social stigma.

Mango offers a sublingual, fast-dissolving tablet that delivers active compounds without the pharmacy line or blue-pill branding. The rapid-onset format avoids liver metabolism for quicker effect and a smoother user experience.

Available in two primary formulations-Sildenafil Mango and Tadalafil Mango -each product combines a proven PDE5 inhibitor with L-arginine for enhanced blood flow and oxytocin for emotional connection. This combination represents a deliberate move away from single-ingredient solutions, toward more comprehensive sexual wellness.

Addressing Hormonal Health Through Oral TRT

The focus on real-world practicality continues with Mangoceuticals' approach to testosterone replacement therapy (TRT). Low testosterone is often under-diagnosed or left untreated, in part because existing treatments-such as injections or topical gels-can be inconvenient, uncomfortable, or difficult to manage.

Prime by MangoRx introduces a more approachable alternative. At its core is Kyzatrex™, an FDA-approved oral testosterone capsule. Designed to deliver a consistent, daily dose without the hormonal spikes associated with other delivery methods, it offers a smoother, more manageable path to hormone balance.

Through the company's integrated telehealth platform, patients can complete lab work, consultations, and prescription fulfillment entirely from home. This ease of access helps remove longstanding barriers to care-bringing more people into the fold who may have previously felt excluded.

Hair Loss Solutions with a Functional Edge

As part of its broader expansion, Mangoceuticals has also entered the hair restoration market-a segment traditionally dominated by topical foams, shampoos, and overstated promises.

Grow by MangoRx is structured differently. Delivered as a mint-flavored, pharmaceutical-grade chewable, it contains a synergistic blend of minoxidil (to encourage growth), finasteride (to reduce DHT), biotin (for structure), and vitamin D3 (to support follicle health). This comprehensive stack addresses both the cause and symptoms of hair loss in a convenient daily format.

Rather than introducing another product that treats hair health as a cosmetic issue, Grow approaches it as a clinical concern with psychological and emotional dimensions. That distinction may prove significant, as the global hair restoration market surpassed $6 billion in 2023 and is projected to grow at a CAGR of 16% through 2030.

Metabolic Health Without the Needle

Expanding beyond core categories, Mangoceuticals has also stepped into one of the fastest-growing areas in wellness: weight management. Rather than replicating existing solutions, the company is working to reduce access barriers with two complementary approaches.

The first is Slim by MangoRx, a dissolvable sublingual tablet that delivers Semaglutide-the same GLP-1 receptor agonist found in drugs like Ozempic and Wegovy. Combined with Vitamin B6, Slim offers a non-injectable, frictionless option for those looking to manage appetite and improve metabolic outcomes.

Alongside Slim, Mangoceuticals has secured exclusive rights in the U.S. and Canada to Diabetinol®, a citrus-derived nutraceutical containing nobiletin and tangeretin. These naturally occurring compounds are being explored for their potential to improve insulin sensitivity, lower glucose production, and reduce inflammation-making them a promising adjunct or alternative for those priced out of prescription GLP-1s.

An Integrated Ecosystem, Not Just a Product Line

Viewed together, these offerings suggest Mangoceuticals is building more than a portfolio-it's constructing a wellness infrastructure. The company's blend of telehealth, clinically relevant formulations, and lifestyle-compatible delivery formats reflects a broader ambition: to modernize personal health by design, not default.

At a time when many players in the wellness space lean heavily on branding or trend alignment, Mangoceuticals is emphasizing something else entirely: evidence-backed design, category-specific innovation, and patient-centric service.

Its long-term trajectory remains to be seen, but the early signals suggest that the company is operating from a different playbook-one focused not on rebranding old solutions, but on redefining what effective care can look like in the modern era.

Sources and references:

• https://www.mangoceuticals.com/

• https://mangorx.com/Product/Sildenafil

• https://mangorx.com/Product/Tadalafil

• https://mangorx.com/Product/Prime

• https://mangorx.com/Product/Grow

• https://feeds.issuerdirect.com/news-release.html?newsid=7113439217978531&symbol=MGRX

• https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/erectile-dysfunction/#:~:text=The%20study%20demonstrated%20that%20ED,are%20affected%20at%20age%2070.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC7097805/#:~:text=Sildenafil%20started%20clinical%20development%20as,oral%20treatment%20for%20erectile%20dysfunction.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10374179/

• https://feeds.issuerdirect.com/news-release.html?newsid=4613443448262254&symbol=MGRX

• https://www.grandviewresearch.com/industry-analysis/hair-restoration-market

• https://blog.marketresearch.com/33.8-billion-u.s.-medical-weight-loss-market-now-dominated-by-glp-1-drugs

• https://mangorx.com/about-us

• https://feeds.issuerdirect.com/news-release.html?newsid=7591101556435216&symbol=MGRX

Additional Disclaimers and Disclosures: This is sponsored content. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares in Mangoceuticals Inc. Always do your own due diligence prior to investing in any publicly traded company. While HPM does not own or market shares, it is prudent to expect that those hiring HPM including that company's owners, employees, third-parties, and affiliates, may sell some or even all of the Mangoceuticals Inc. shares that they own, if any, during and/or after the engagement period listed in this disclosure. Specifically, Hawk Point Media Group, LLC. (HPM) has been compensated four-thousand-dollars via wire transfer from Shore Thing Media Group, Llc. to produce, manage, and distribute content about Mangoceuticals for a one-day period beginning on April 23, 2025 and ending on April 24, 2025. Always do your own due diligence prior to investing in any publicly traded company. Forward-Looking Statements: This article contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Sources and references:

• https://www.mangoceuticals.com/

• https://mangorx.com/Product/Sildenafil

• https://mangorx.com/Product/Tadalafil

• https://mangorx.com/Product/Prime

• https://mangorx.com/Product/Grow

• https://feeds.issuerdirect.com/news-release.html?newsid=7113439217978531&symbol=MGRX

• https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/erectile-dysfunction/#:~:text=The%20study%20demonstrated%20that%20ED,are%20affected%20at%20age%2070.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC7097805/#:~:text=Sildenafil%20started%20clinical%20development%20as,oral%20treatment%20for%20erectile%20dysfunction.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10374179/

• https://feeds.issuerdirect.com/news-release.html?newsid=4613443448262254&symbol=MGRX

• https://blog.marketresearch.com/33.8-billion-u.s.-medical-weight-loss-market-now-dominated-by-glp-1-drugs

• https://mangorx.com/about-us

• https://feeds.issuerdirect.com/news-release.html?newsid=7591101556435216&symbol=MGRX

Additional Disclaimers and Disclosures: This is sponsored content. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares in Mangoceuticals Inc. Always do your own due diligence prior to investing in any publicly traded company. While HPM does not own or market shares, it is prudent to expect that those hiring HPM including that company's owners, employees, third-parties, and affiliates, may sell some or even all of the Mangoceuticals Inc. shares that they own, if any, during and/or after the engagement period listed in this disclosure. Specifically, Hawk Point Media Group, LLC. (HPM) has been compensated four-thousand-dollars via wire transfer from Shore Thing Media Group, Llc. to produce, manage, and distribute content about Mangoceuticals for a one-day period beginning on April 23, 2025 and ending on April 24, 2025. Always do your own due diligence prior to investing in any publicly traded company. Forward-Looking Statements: This article contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Media contact for this content:

info@hawkpointmedia.com

SOURCE: Mangoceuticals Inc.

View the original press release on ACCESS Newswire